Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $9.79M
• Dividend Yield: N/A
• Average Volume (3M): 154.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 65
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -65.57
• Shares Outstanding: 3,038,853
• 10 Day Avg. Volume: 115,442
• 30 Day Avg. Volume: 154,442
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 42.65
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.00
• Price Target Upside: 320.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Mainz Biomed B.V. faces significant financial hurdles, including negative profitability and high leverage. The stock is in a strong downtrend, as indicated by technical analysis. Valuation metrics also reflect the company's unprofitable status. Collectively, these factors suggest a high-risk investment with a need for strategic improvements to stabilize long-term performance.

Positive Factors

Clinical Study

Mainz Biomed announced the enrollment of the first subject into the eAArly DETECT 2 clinical study in the US.

Partnerships

An agreement with Quest Diagnostics has been signed for the ReconAAsense study with an option for commercialization.

Product Development

Mainz Biomed's Next Generation Test uses mRNA and FIT to enhance detection rates for advanced adenomas, showing improved results compared to industry standards.

Negative Factors

Capital Needs

The company needs to raise a significant amount of capital to complete the eAArly DETECT 2 and a pivotal study before regulatory submission.

Financial Performance

Net loss totaled $11.0M in the first half of the year, with revenue being only $0.5M, indicating financial challenges.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V. (MYNZ) is a molecular genetics diagnostic company focused on the early detection of cancer. The company specializes in developing and commercializing high-quality, non-invasive diagnostic tools for various cancer types, particularly colorectal cancer. Its flagship product is a diagnostic test designed to detect early signs of colorectal cancer through innovative molecular biology solutions.

How the Company Makes Money

Mainz Biomed generates revenue through the sale of its proprietary diagnostic tests to healthcare providers, clinics, and laboratories. The company's primary revenue stream is derived from the commercialization of its flagship colorectal cancer screening test. Additionally, Mainz Biomed engages in strategic partnerships and collaborations with research institutions and healthcare organizations to enhance and expand its diagnostic offerings. These partnerships may contribute to revenue through joint development agreements, licensing deals, and the sharing of research findings that support product innovation and market expansion.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. operates in the Medical Diagnostics & Screening industry and faces considerable financial difficulties. While there is some revenue growth and improvement in gross profit margin, the company is struggling with substantial losses and cash flow issues. The high leverage and low equity base pose additional risks, potentially impacting its financial health and operational sustainability.

Income Statement

Mainz Biomed B.V. has shown some revenue growth over time; however, the company remains unprofitable with negative EBIT and net income consistently. The gross profit margin improved from previous years, but the net profit margin is substantially negative, indicating significant operational challenges.

Balance Sheet

The company's balance sheet shows an improvement in stockholders' equity over the years, yet it remains highly leveraged with a rising debt-to-equity ratio. The equity ratio is very low, reflecting potential risks in financial stability.

Cash Flow

The operating cash flow is persistently negative, and free cash flow has worsened over the years. The company faces significant challenges in generating cash from operations, which indicates potential liquidity issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
735.53K	895.48K	529.88K	577.35K	493.56K	281.39K
	Gross Profit
359.29K	509.66K	182.15K	177.62K	123.08K	-61.27K
	EBIT
-16.40M	-26.64M	-26.17M	-9.38M	-325.81K	-921.91K
	EBITDA
-14.16M	-25.01M	-25.72M	-11.28M	-257.64K	-702.08K
	Net Income Common Stockholders
-16.21M	-26.30M	-26.45M	-12.07M	-886.18K	-1.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
122.57K	7.07M	17.14M	8.73M	122.57K	203.59K
	Total Assets
673.27K	15.41M	20.24M	10.04M	673.27K	715.96K
	Total Debt
2.98M	7.42M	3.23M	2.58M	2.98M	2.41M
	Net Debt
2.86M	349.86K	-13.91M	-6.15M	2.86M	2.21M
	Total Liabilities
3.41M	12.16M	6.14M	3.68M	3.41M	2.67M
	Stockholders Equity
-2.74M	3.25M	14.10M	6.36M	-2.74M	-1.95M
Cash Flow		Free Cash Flow
-13.18M	-23.84M	-15.43M	-3.24M	-478.42K	-416.50K
	Operating Cash Flow
-12.80M	-21.94M	-14.77M	-3.22M	-468.74K	-416.50K
	Investing Cash Flow
-794.95K	-1.90M	-658.48K	1.20M	-9.69K	0.00
	Financing Cash Flow
6.02M	14.23M	23.94M	10.61M	396.68K	424.00K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 3.33 is below the 20-day moving average (MA) of 3.76, below the 50-day MA of 5.05, and below the 200-day MA of 9.22, indicating a bearish trend. The MACD of -0.55 indicates Positive momentum. The RSI at 29.46 is Positive, neither overbought nor oversold. The STOCH value of 11.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMO	76 Outperform	$161.36B	25.84	13.15%	0.36%	0.05%	6.87%
QGEN	66 Neutral	$8.66B	113.00	2.27%	―	0.66%	-75.89%
EXAS	52 Neutral	$8.26B	―	-37.09%	―	10.37%	-389.98%
ILMN	49 Neutral	$11.28B	―	-30.11%	―	-2.93%	-4.69%
GH	49 Neutral	$5.08B	―	-4584.47%	―	31.04%	16.91%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
MYNZ	42 Neutral	$9.79M	―	-809.29%	―	―	―